Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | TTK | P33981 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 12/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | FPR1 | P21462 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28223511 | 0.77 | AURKA (0.52) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL174142 | 0.77 | BRD4 (0.35) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL15006071 | 0.76 | AURKA (0.50) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL2118787 | 0.76 | BRD4 (0.50) | BRD4HTTBRD9 | |
| SCHEMBL1856897 | 0.74 | HDAC8 (0.35) | BRD4HTTTP53HDAC8 | |
| SCHEMBL16478319 | 0.74 | MAP2K1 (0.41) | BRD4HTTMAP2K1 | |
| SCHEMBL13078611 | 0.74 | HTT (0.33) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL16651268 | 0.74 | BRD4 (0.39) | BRD4HTTMAP2K1HDAC8 | |
| SCHEMBL16339860 | 0.74 | HTT (0.33) | AURKATTKAURKBINCENPBRD4 | |
| SCHEMBL13456010 | 0.74 | AURKA (0.49) | AURKATTKAURKBINCENPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | INTERLINE THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| CN-120004902-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | SICHUAN HUIYU PHARMACEUTICAL CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| CN-119930630-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119925375-A | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119698416-A | Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors | 英特莱治疗公司 | 2025-03-25 | — | — | CN | disclosed |
| EP-4518974-A1 | IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | Interline Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-115151535-B | Heteroaryl heterocycles and uses thereof | 和记黄埔医药（上海）有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20240398791-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-12-05 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033854-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033857-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033857-A2 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1861399-A2 | CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006099268-A2 | CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | AURKA 605/4885TTK 2348/4885AURKB 329/4885 |
| US-20240398791-A1 | HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP3A43, CYP3A5, CYP11B2 | AURKA 2976/4885TTK 3857/4885AURKB 2212/4885 |
| US-20250346593-A1 | IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS | RIPK2, RIPK1, RIPK4 | AURKA 660/4885TTK 728/4885AURKB 546/4885 |
| US-20250145589-A1 | PYRIDINE DERIVATIVE AND USE THEREOF | KRAS, NRAS, BRAF | AURKA 773/4885TTK 470/4885AURKB 826/4885 |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | AURKA 605/4885TTK 2348/4885AURKB 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.